Market Newsdesk

Saint-Herblain (France), December 16, 2020 – Valneva SE, a specialty vaccine company focused on prevention against diseases with major unmet needs, today announced the initiation of a Phase 1/2 clinical study for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.

VLA2001 leverages the manufacturing platform of Valneva’s licensed Japanese encephalitis vaccine, IXIARO^® and is the first publicly announced inactivated vaccine against COVID-19 to commence clinical development in Europe.

The VLA2001-201 study is a randomized, double blind and placebo-controlled trial evaluating the safety and immunogenicity for three dose levels in approximately 150 healthy adults.

The study will be conducted in study sites across the United Kingdom and is supported by the National Institute for Health Research (NIHR).

The primary endpoint read-out will be two weeks after completion of the two-dose primary immunization (day 0, 21). Subject to analysis of this data, including the selection of the optimal dose currently expected in the early second quarter of 2021, additional trials are expected to commence immediately thereafter.

The Company currently plans to include more than 4,000 participants in additional trials, which it believes could support an initial regulatory approval as soon as the fourth quarter of 2021.

Alok Sharma, UK
Secretary of State for Business, Energy and Industrial Strategy, said, “As we take the monumental steps in rolling out the first COVID-19 vaccine, we must remember that we need to have a range of vaccines available to protect the British public now and long into the future. Today, we have more welcome news that life-saving clinical trials will begin across the country to test the safety and effectiveness of Valneva’s vaccine, which is being clinically developed right here in the UK. Having visited Valneva’s state-of-the art facility in the summer, I have seen first-hand the incredible work our scientists and researchers are doing to develop this vaccine. Thanks to significant investment from the UK government, we are doing all we can to ensure our country has the capabilities in place to produce hundreds of millions of doses of this vaccine for the UK, and for those around the world.”

Thomas Lingelbach, Chief Executive Officer of Valneva, added, “Our teams have been working extremely hard to develop our differentiated vaccine candidate and I would like to thank them, as well as the UK government, for their dedication and support. While conducting our first clinical trials, we are already ramping-up our manufacturing capacities and commencing production at full-scale so that we can make the vaccine widely available across the world assuming the vaccine is safe and effective.”

Adam Finn,
Chief investigator for the VLA 2001-201 program, Professor of Paediatrics at the University of Bristol and Consultant at the Bristol Royal Hospital for Children said, “I’m very pleased and proud to be leading the clinical trials effort to bring this vaccine forward in the UK working alongside a very strong team across several National Institute for Health Research NHS sites. The effort to produce vaccines to prevent COVID-19 and to limit its spread within populations has included several very new approaches, but there are tried and tested approaches to developing highly effective and safe vaccines that we can also use. Growing the whole virus and then inactivating it to make a vaccine is an approach first developed in the 1950s and has contributed to disease prevention over many decades. We expect this inactivated vaccine containing two adjuvants could generate a broader immune response.”

In September 2020, Valneva announced a major COVID-19 vaccine partnership with the U.K. government. Under the agreement, if vaccine development is successful, Valneva will provide the UK government with 60 million doses in the second half of 2021 and UK government has options over provision of a further 130 million doses from 2022-2025. UK government is also investing up-front in the scale up and development of the vaccine, with the investment being recouped against the vaccine supply.

About the Novel Coronavirus SARS-CoV-2 and COVID-19 Disease

SARS-CoV-2 is a new coronavirus identified in late 2019 and belongs to a family of enveloped RNA viruses that include MERS and SARS, both of which caused serious human infections of the respiratory system. The virus, which causes a disease named COVID-19, has never before been found in humans. Since this outbreak was first reported, the virus has caused over 1.6 million reported deaths globally. It has been declared a pandemic by the World Health Organization (WHO).

About VLA2001-201

VLA2001-201 is the first-in-human Phase 1/2 study that will evaluate three dose levels of VLA2001 (low, medium, high) for safety, tolerability and immunogenicity in a two-dose schedule with intra muscular vaccinations three weeks apart. Overall, 150 healthy young adults aged 18 to 55 years will be recruited. The study will start with an open-label dose-escalation phase. Following review of safety data by an independent Data Safety Monitoring Board (DSMB), the study will be conducted as a randomized, double-blind, multicenter study. VLA2001-201 is conducted in two parts: Part A (Day 1 to Day 36) and Part B (Day 37 to Day 208). Following an evaluation of Part A data (i.e., data up to Day 36) from the present study, further clinical studies may be initiated.

About VLA2001

VLA2001 is Valneva’s vaccine candidate against the SARS-CoV-2 virus. VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018. This adjuvant combination has consistently induced higher antibody levels in preclinical experiments than alum-only formulations and shown a shift of the cellular immune response towards Th1. VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging the manufacturing technology for Valneva’s licensed Japanese Encephalitis Vaccine, IXIARO^®. The process, which has already been upscaled to final industrial scale, includes inactivation with BPL to preserve the native structure of the S-protein. CpG 1018 is a component of the US FDA-approved HEPLISAV-B^® vaccine.
VLA2001 vaccine is expected to conform with standard cold chain requirements (2 degrees to 8 degrees centigrade).

About Valneva SE

Valneva is a specialty vaccine company focused on prevention against diseases with major unmet needs. Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO^®/JESPECT^® indicated for the prevention of Japanese encephalitis and DUKORAL^® indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has various vaccines in development including unique vaccines against Lyme disease, chikungunya and COVID-19. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the US with over 500 employees.  For more information, visit www.valneva.com and follow the Company on LinkedIn.

Valneva Investor and Media Contacts Laetitia Bachelot-Fontaine Director Investor Relations & Corporate Communications M +33 (0)6 4516 7099 [email protected]

Teresa Pinzolits Corporate Communications Specialist T +43 (0)1 20620 1116 [email protected]

Valneva Forward-Looking Statements

This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to the progress, timing and completion of research, development and clinical trials for product candidates, the ability to manufacture, market, commercialize and achieve market acceptance for product candidates, the ability to protect intellectual property and operate the business without infringing on the intellectual property rights of others, estimates for future performance and estimates regarding anticipated operating losses, future revenues, capital requirements and needs for additional financing. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be indicative of their in the future. In some cases, you can identify forward-looking statements by words such as “could,” “should,” “may,” “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “targets,” or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made during this presentation will in fact be realized. Valneva is providing the information in these materials as of this press release, and disclaim any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Attachment

• 2020_12_16_VLA2001_Phase1-2_Initiation_PR_EN_Final

Equinor (OSE: EQNR, NYSE: EQNR) announces that Ulrica Fearn is appointed chief financial officer (CFO) and executive vice president, with effect from 16 June 2021. Fearn will succeed acting CFO Svein Skeie, who will become senior vice president CFO Performance Management and Risk with effect from the same date.

Fearn is currently Director of Group Finance at BT Plc, where she has helped drive cultural change and strong sustainable performance since 2017.

“I am pleased to welcome Ulrica to Equinor and our leadership team. Her deep and extensive experience in leading financial operations, as well as driving operational, control and shared services results, will make a strong contribution to the leadership of Equinor. She also brings renewal and increased diversity to the Corporate Executive Committee. She is guided by her strong values and I am confident Ulrica will provide good leadership as we position Equinor for the future,” says Anders Opedal, president and CEO of Equinor.

At BT, Fearn with a focus on profit and loss, balance sheet and cash flow performance, led the development and implementation of a finance transformation programme. This has involved a new group-wide information model, control frameworks, and enhanced reporting.

Prior to BT, Fearn built an international career at Diageo Plc. Originally joining them in 1998, she took leadership roles of increasing responsibility covering treasury, internal audit, and finance business partnering. Her career at Diageo culminated in general management responsibility for global shared services. Here she led the expansion of the service offering whilst upgrading performance to position the operation as a premier global shared services operation.

“I am thrilled to join Equinor and return to my native Scandinavia. Equinor has a strong business, a strong position, a proud history, and an exciting change journey ahead. I look forward to working with the team to further strengthen the company,” says Ulrica Fearn.

As CFO, Fearn will lead Equinor’s global finance organisation and be responsible for treasury and tax, investor relations, performance management and risk, accounting and financial compliance, business development and corporate mergers and acquisitions, corporate strategy and global business services.

Fearn holds a master’s degree in business and finance from the University of Halmstad.

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Nokia Corporation
Stock Exchange Release
December 16, 2020, at 08:00 (CET +1)

Nokia provides a mid-point update on strategy and operating model

• Nokia aligns to deliver critical networks to CSPs, enterprises and webscales.
• Company aims for technology leadership in all segments it chooses to play in.
• Nokia sees value gradually migrating from monolithic systems towards silicon, cloud-native software and services, and the industry moving towards as-a-service business models.
• Provides transparency on expected operating margin performance of its four new business groups in 2021. Previously provided outlook for 2020 and 2021 remain unchanged.

Espoo, Finland – Today Nokia provides an update on its strategy and operating model. On October 29 Nokia announced the first phase of its new strategy, outlining high-level strategic principles alongside a new operating model designed to better position the company for changing markets and align with customer needs. The new model is effective from January 1, 2021. Detailed business group strategies will be provided on Capital Markets Day on March 18, 2021.

Our focus areas

“We are positioning Nokia to lead in a changing world,” says Pekka Lundmark, President and CEO of Nokia.

“The world faces big problems: environmental issues, resource scarcity, inequality and stalling productivity. Technology will be an essential part of the solution. As a result, we will see an increase in critical networks, which will extend to all corners of society.”

Critical networks are advanced networks that run mission-critical services for companies and societies. They are becoming increasingly important and extending to all corners of society. This means that Nokia’s addressable market for critical networks with CSPs, webscales and enterprises is also extending.

Customers are using a best-of-breed approach to build these networks, selecting network elements from multiple individual vendors who are able to offer the best performance per total cost of ownership. Nokia is aiming to be the technology leader in the areas it chooses to play in.

“We are well positioned to be a trusted partner for critical networks. We are experienced in creating both carrier-grade performance networks and working with the world’s most demanding webscales. We have a strong position in technologies that are important for critical networks, such as open and virtualized radio access networks and we are on course for a 100% cloud-native software portfolio,” says Lundmark.

Nokia also sees a market evolution where value in critical networks will gradually shift from monolithic systems towards silicon, software and services; where the importance of cloud-native and open solutions will increase; and where value will be captured through different business models.

“We are one of the leading network equipment providers to evolve monolithic core networks to virtualized core networks that are fully cloud-native.

One of our focus areas will be to continue building out our capabilities in this area to ensure technology and market leadership. We are well positioned to pivot to new business models as our customers’ needs evolve and require more as-a-service solutions,” says Lundmark.

Continuing to strengthen Nokia’s long-term research and global patent portfolio is a key element in securing technology leadership. Nokia’s ambition is to lead in all domains including innovation, products, standardization and patents.

“Committing to long-term investment in research and innovation will allow us to anticipate and capitalize on industry changes and position us at the front of the pack when new technology windows open.”

Providing transparency to Nokia’s four new business groups

Today, Nokia provided its assumptions for its four new business groups and Group Common and Other in 2021 and over the longer term. The company will discuss the addressable markets, competitive positions and strategic focus areas for each business group during its strategy webcast to analysts.

Nokia’s previously provided outlook for 2020 and 2021 remains unchanged. In connection with its Q3 2020 results, Nokia expects comparable* operating margin of 7-10% in 2021.

Nokia intends to provide recast comparative segment results for 2020 by mid-March 2021 and more detailed information at its Capital Markets Day on March 18, 2021.

• Mobile Networks’ immediate focus will be on executing its turnaround and regaining 5G leadership. It will focus on leadership in ORAN and vRAN, maintaining scale with CSP customers and growing its enterprise-dedicated Private Wireless Networks business. It is expected to deliver comparable* operating margin of around zero percent in 2021, and significant improvement over the longer term.
• Network Infrastructure (previously IP and Fixed Networks) will focus on the building blocks and essential solutions of critical networks, using its technology leadership in IP Networks, Optical Networks, Fixed Networks, and Alcatel Submarine Networks to drive digitalization across all industries. It is expected to deliver comparable* operating margin in the high single digit range in 2021, and gradual improvement over the longer term.
• Cloud and Network Services creates value for both service providers and enterprise customers as demand for critical networks accelerates, leading the transition to cloud-native software and as-a-service delivery models. It is expected to deliver comparable* operating margin in the mid-single digit range in 2021, and significant improvement over the longer term.
• Nokia Technologies will continue to monetize and grow the value of Nokia’s intellectual property and licensing revenue by investing in innovation and its world-leading patent portfolio as well as pursuing other licensing opportunities. It is expected to deliver a slight improvement in comparable* operating profit in 2021, relative to 2020, and stable performance over the longer term.
• Group Common and Other, which predominately consists of corporate costs, is expected to be run in a lean manner, with costs directly embedded into the business groups whenever possible. Group Common and Other is expected to deliver a comparable* operating loss of approximately €200 million in 2021.

*Comparable results exclude amortization of acquired intangibles, restructuring and other items affecting comparability. This information provided reflects Nokia’s new operating model, effective January 1, 2021.

Webcast details

Nokia’s strategy webcast for analysts will begin on December 16, 2020, at 3 p.m. EET. A link to the webcast will be available at www.nokia.com/financials. Media representatives can listen in via the link, or alternatively call +1 412 717 9224.

Note: Proposed organizational changes referenced in this release may be subject to consultation with employee representatives in certain jurisdictions and are not considered final until such processes are completed.

Investor inquiries

Nokia Investor Relations
Tel.: +358 40 803 4080
Email: [email protected]

Media inquiries

Nokia Communications
Tel.: +358 10 448 4900
Email: [email protected]

About Nokia

We create the critical networks and technologies to bring together the world’s intelligence, across businesses, cities, supply chains and societies.

With our commitment to innovation and technology leadership, driven by the award-winning Nokia Bell Labs, we deliver networks at the limits of science across mobile, infrastructure, cloud, and enabling technologies.

Adhering to the highest standards of integrity and security, we help build the capabilities we need for a more productive, sustainable and inclusive world.

For our latest updates, please visit us online www.nokia.com and follow us on Twitter @nokia.

FORWARD-LOOKING STATEMENTS


It should be noted that Nokia and its businesses are exposed to various risks and uncertainties and certain statements herein that are not historical facts are forward-looking statements. These forward-looking statements reflect Nokia’s current expectations and views of future developments and include statements regarding: A) expectations, plans or benefits related to our strategies, growth management and operational key performance indicators; B) expectations, plans or benefits related to future performance of our businesses (including the expected impact, timing and duration of that impact of COVID-19 on our businesses, our supply chain and our customers’ businesses) and any future dividends including timing and qualitative and quantitative thresholds associated therewith; C) expectations and targets regarding financial performance, cash generation, results, the timing of receivables, operating expenses, taxes, currency exchange rates, hedging, cost savings, product cost reductions and competitiveness, as well as results of operations including targeted synergies, better commercial management and those results related to market share, prices, net sales, income and margins; D) expectations, plans or benefits related to changes in organizational and operational structure; E) expectations regarding competition within our market, market developments, general economic conditions and structural and legal change globally and in national and regional markets, such as China; F) our ability to integrate acquired businesses into our operations and achieve the targeted business plans and benefits, including targeted benefits, synergies, cost savings and efficiencies; G) expectations, plans or benefits related to any future collaboration or to business collaboration agreements or patent license agreements or arbitration awards, including income to be received under any collaboration or partnership, agreement or award; H) timing of the deliveries of our products and services, including our short term and longer term expectations around the rollout of 5G, investment requirements with such rollout, and our ability to capitalize on such rollout; I) expectations and targets regarding collaboration and partnering arrangements, joint ventures or the creation of joint ventures, and the related administrative, legal, regulatory and other conditions, as well as our expected customer reach; J) outcome of pending and threatened litigation, arbitration, disputes, regulatory proceedings or investigations by authorities; K) expectations regarding restructurings, investments, capital structure optimization efforts, uses of proceeds from transactions, acquisitions and divestments and our ability to achieve the financial and operational targets set in connection with any such restructurings, investments, capital structure optimization efforts, divestments and acquisitions, including our current cost savings program; L) expectations, plans or benefits related to future capital expenditures, reduction of support function costs, temporary incremental expenditures or other R&D expenditures to develop or rollout software and other new products, including 5G, ReefShark and increased digitalization; M) expectations regarding our customers’ future actions, including our customers’ capital expenditure constraints and our ability to satisfy customer’s needs and retain their business; and N) statements preceded by or including “believe”, “expect”, “expectations”, “deliver”, “maintain”, “strengthen”, “target”, “estimate”, “plan”, “intend”, “assumption”, “focus”, “continue”, “should”, “will” or similar expressions. These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond our control, which could cause our actual results to differ materially from such statements. These statements are based on management’s best assumptions and beliefs in light of the information currently available to them. These forward-looking statements are only predictions based upon our current expectations and views of future events and developments and are subject to risks and uncertainties that are difficult to predict because they relate to events and depend on circumstances that will occur in the future. Factors, including risks and uncertainties that could cause these differences include, but are not limited to: 1) our strategy is subject to various risks and uncertainties and we may be unable to successfully implement our strategic plans, sustain or improve the operational and financial performance of our business groups, correctly identify or successfully pursue business opportunities or otherwise grow our business; 2) general economic and market conditions, general public health conditions (including its impact on our supply chains) and other developments in the economies where we operate, including the timeline for the deployment of 5G and our ability to successfully capitalize on that deployment; 3) competition and our ability to effectively and profitably invest in existing and new high-quality products, services, upgrades and technologies and bring them to market in a timely manner; 4) our dependence on the development of the industries in which we operate, including the cyclicality and variability of the information technology and telecommunications industries and our own R&D capabilities and investments; 5) our dependence on a limited number of customers and large multi-year agreements, as well as external events impacting our customers including mergers and acquisitions and the possibility of our customers awarding business to our competitors; 6) our ability to maintain our existing sources of intellectual property-related revenue through our intellectual property, including through licensing, establishing new sources of revenue and protecting our intellectual property from infringement; 7) our ability to manage and improve our financial and operating performance, cost savings, competitiveness and synergies generally, expectations and timing around our ability to recognize any net sales and our ability to implement changes to our organizational and operational structure efficiently; 8) our global business and exposure to regulatory, political or other developments in various countries or regions, including emerging markets and the associated risks in relation to tax matters and exchange controls, among others; 9) our ability to achieve the anticipated benefits, synergies, cost savings and efficiencies of acquisitions; 10) exchange rate fluctuations, as well as hedging activities; 11) our ability to successfully realize the expectations, plans or benefits related to any future collaboration or business collaboration agreements and patent license agreements or arbitration awards, including income to be received under any collaboration, partnership, agreement or arbitration award; 12) Nokia Technologies’ ability to protect its IPR and to maintain and establish new sources of patent, brand and technology licensing income and IPR-related revenues, particularly in the smartphone market, which may not materialize as planned, 13) our dependence on IPR technologies, including those that we have developed and those that are licensed to us, and the risk of associated IPR-related legal claims, licensing costs and restrictions on use; 14) our exposure to direct and indirect regulation, including economic or trade policies, and the reliability of our governance, internal controls and compliance processes to prevent regulatory penalties in our business or in our joint ventures; 15) our reliance on third-party solutions for data storage and service distribution, which expose us to risks relating to security, regulation and cybersecurity breaches; 16) inefficiencies, breaches, malfunctions or disruptions of information technology systems, or our customers’ security concerns; 17) our exposure to various legal frameworks regulating corruption, fraud, trade policies, and other risk areas, and the possibility of proceedings or investigations that result in fines, penalties or sanctions; 18) adverse developments with respect to customer financing or extended payment terms we provide to customers; 19) the potential complex tax issues, tax disputes and tax obligations we may face in various jurisdictions, including the risk of obligations to pay additional taxes; 20) our actual or anticipated performance, among other factors, which could reduce our ability to utilize deferred tax assets; 21) our ability to retain, motivate, develop and recruit appropriately skilled employees; 22) disruptions to our manufacturing, service creation, delivery, logistics and supply chain processes, and the risks related to our production sites; 23) the impact of litigation, arbitration, agreement-related disputes or product liability allegations associated with our business; 24) our ability to re-establish investment grade rating or maintain our credit ratings; 25) our ability to achieve targeted benefits from, or successfully implement planned transactions, as well as the liabilities related thereto; 26) our involvement in joint ventures and jointly-managed companies; 27) the carrying amount of our goodwill may not be recoverable; 28) uncertainty related to the amount of dividends and equity return (if any) we are able to distribute to shareholders for each financial period; 29) pension costs, employee fund-related costs, and healthcare costs; 30) our ability to successfully complete and capitalize on our order backlogs and continue converting our sales pipeline into net sales; 31) risks related to undersea infrastructure; and 32) the scope and duration of the COVID-19 impact on the global economy and financial markets as well as our customers, supply chain, product development, service delivery, other operations and our financial, tax, pension and other assets, and the shape of the economic recovery following the pandemic as well as the risk factors specified in our 2019 annual report on Form 20-F published on March 5, 2020 under “Operating and financial review and prospects-Risk factors” as supplemented by the form 6-K published on April 30, 2020 under the header “Risk Factors” and in our other filings or documents furnished with the U.S. Securities and Exchange Commission. Other unknown or unpredictable factors or underlying assumptions subsequently proven to be incorrect could cause actual results to differ materially from those in the forward-looking statements. We do not undertake any obligation to publicly update or revise forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent legally required.

 

VANCOUVER, British Columbia, Dec. 16, 2020 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company, is pleased to announce that it has begun to build-out the 4^th unit in its facility for the extraction of mushrooms and to commence research and development of psilocybin under a Dealer’s Licence.

The Company is preparing an application to Health Canada for a Dealer’s Licence under the Controlled Drugs and Substances Act (CDSA), which provides, among other things, the framework for legal access to controlled substances, and the control and regulation of production, distribution and sale of psilocybin.

Under this framework, a company is required to obtain a licence issued by Health Canada in order to conduct various activities with controlled substances. Licence holders are responsible for compliance with the CDSA and its Regulations as well as compliance with other applicable federal, provincial and territorial legislation and municipal by-laws. The issued licence dictates activities, conditions, and restrictions for the licence holder depending on licence permissions.

A Dealer’s Licence could allow for the following activities:

• Procurement of controlled substances, including by import, synthesis, propagation, cultivation and harvesting of psychedelic mushrooms for psilocybin extraction
• Research and manufacture of controlled substances such as psilocybin and psilocin
• Business to business sale of controlled substances, including by export
• Sale of controlled substance via pharmacies

Pure Extracts CEO, Ben Nikolaevsky, remarked, “As a plant-based extractor bringing functional mushroom products to market in Q1 2021, we are very excited to be building-out our facility for our move into the controlled substances world of psychedelics. It’s great to have space adjacent to our cutting-edge facility which is built to Health Canada standards and to know that this space will also have the same high standards of construction that Pure Extracts prides itself on.”

Having the ability to do extraction research and development into psychedelic compounds such as psilocybin and psilocin will prepare Pure Extracts to work with partners such as medical doctors, pharmaceutical company and pharmacies as clinical trials lead to the legalization of psychedelics and the advancement of micro-dosing in the near future.

Submission of the Company’s Dealer’s License application is subject to compliance with applicable securities laws, including any necessary approvals by the CSE.

About Pure Extracts

(CSE: PULL) (XFRA: A2QJAJ)

The Company features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. On September 25, 2020, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act and the Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020. Find out more at https://pureextractscorp.com/.

For further information please contact Empire Communications Group at (604) 343-2724.

ON BEHALF OF THE BOARD

“

Ben Nikolaevsky

”

Ben Nikolaevsky
CEO and Director

The CSE has neither approved nor disapproved the contents of this press release.

This news release contains forward-looking statements relating to the future operations of Pure Extracts, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. The Company is in the preliminary stages of preparing a Dealer’s License application and there is no certainty on the timing of such application, or that the Company will ultimately be successful in obtaining a Dealer’s License. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of Pure Extracts include risks detailed from time to time in the filings made by Pure Extracts under securities regulations. 

FREMONT, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) — The LoRa Alliance^®, the global association of companies backing the open LoRaWAN^® standard for the Internet of Things (IoT) low-power wide-area networks (LPWANs), announced that the first episode of its new Destination LoRaWAN webinar series, sponsored by MachineQ, a Comcast Company; Birdz; and Charter Communications, will kick off this morning, December 16, 2020, with three regional broadcasts at 10 am local time in China (CST), Europe (CET) and the United States (PST).

Destination LoRaWAN will showcase the incredible impact LoRaWAN is making in IoT around the world. The series will travel the world, featuring LoRa Alliance members, industry analysts, futurists and technologists who will present on a wide variety of topics throughout 2021. Sessions will be hosted in the language and time zone of each event to highlight the positive effect LoRaWAN is making in local markets around the world and maximize accessibility. The schedule and registration for events taking place in the first half of 2021 is open now.

The first event is focused on “The Power of LoRaWAN”. It will include a look back at the advancements behind LoRaWAN technology in honor of the LoRa Alliance’s fifth anniversary. It will also showcase the myriad achievements of the technology, LoRa Alliance members, and how LoRaWAN is driving business value.

Member companies CareBand, Kerlink, Milesight, and MultiTech will share their LoRaWAN for Good projects illustrating how the technology supports the United Nation’s 17 Sustainable Development Goals. The Amazon Web Services (AWS) keynote will feature Michael MacKenzie, GM, AWS IoT Connectivity & Control Services and Karthik Ranjan, AWS LoRaWAN Ecosystem Leader, who will showcase how AWS is accelerating IoT connectivity with LoRaWAN. The company launched a new platform yesterday that allows users to easily and quickly connect and secure LoRaWAN device fleets at scale and accelerate IoT application development.

“We’re thrilled to be working with the LoRa Alliance,” said Michael MacKenzie, General Manager, AWS IoT Connectivity and Control, Amazon Web Services, Inc. “The LoRaWAN standard offers tremendous flexibility for building or augmenting IoT architectures with a wide range of wireless sensors and static devices.”

“The LoRa Alliance is a global member driven organization and it is amazing to see the innovative LoRaWAN solutions our members are bringing to market to advance their businesses and improve the planet,” said Donna Moore, CEO and Chairwoman of the LoRa Alliance. “I’m very excited to launch the Destination LoRaWAN series, which gives the market an in-depth look at the huge opportunities to transform their businesses and for our members to showcase their products and solutions on the global stage.”

• Register now to join “The Power of LoRaWAN” webinar.
• Visit the Destination LoRaWAN engagement hub to view the current schedule of events and register.
• Learn about the benefits of LoRa Alliance membership here.
• Follow us on Twitter and LinkedIn to stay up to date on the alliance and our members’ activities.

About the LoRa Alliance:

The LoRa Alliance^® is an open, nonprofit association that has become one of the largest and fastest-growing alliances in the technology sector since its inception in 2015. Its members collaborate closely and share expertise to develop and promote the LoRaWAN^® standard, which is the de facto global standard for secure, carrier-grade IoT LPWAN connectivity. LoRaWAN has the technical flexibility to address a broad range of IoT applications, both static and mobile, and a robust LoRaWAN Certification program to guarantee that devices perform as specified. The LoRaWAN standard has been deployed by more than 140 major mobile network operators globally, and connectivity is available in more than 160 countries, with continual expansion. More information: http://lora-alliance.org/

LoRa Alliance^® and LoRaWAN^® are registered trademarks, used with permission.

MEDIA CONTACT
Eric Lawson for LoRa Alliance
[email protected]

ZURICH, Switzerland, Dec. 16, 2020 (GLOBE NEWSWIRE) — Swiss performance sportswear brand On opens its global flagship store today, On NYC, located at 363 Lafayette Street in New York, NY. On has pioneered a design-centric and technologically driven approach to the in-store consumer experience. Centered around its innovative Magic Wall, On NYC provides customers an effortless and explorative new way to shoe shop. Customers are invited to experience On NYC in-person starting today. New York City residents and visitors can also schedule a virtual shopping appointment and receive product within 2-4 hours to try On from the comfort of their homes before purchasing.

“Ten years ago, we set out to revolutionize the running experience. Today, we’ve reinvented the retail experience,” said On Co-Founder David Allemann. “With design and technology at the forefront, On NYC will empower shoppers to engage with our products in an entirely new way. This year more than ever, people have found solace and joy in running. That’s why, in many ways, there has never been a better time for us to open our first global flagship store in a city that we’re confident will remain the shopping capital of the world.”

Upon entering On NYC, shoppers will experience the latest in retail technology. Spanning nearly the store’s length and height, the 62 x 9 x 3 ft. Magic Wall is striking in both appearance and technological capabilities. The frontside of the Magic Wall allows shoppers to analyze their running styles in seconds right on the store floor. With hidden gait-cycle analysis technology, shoppers need to only run a few strides to get instantly matched with the best shoes for their individual running style. Combined with a custom-built invisible foot scanner with depth cameras that achieve an accuracy of +/- 1.25mm, shoppers receive not only the perfect model recommendations but also their perfect size. On’s team of running expert store advisors will be available to facilitate and coach along the way.

The back of the Magic Wall enables shoppers to explore and try on the entirety of the On shoe collection with ease. Carrying every model and size, the Magic Wall revolutionizes shoe shopping by eliminating time spent waiting to receive sizes, a store floor strewn with shoe boxes and allowing for more valuable interaction to learn from On’s expert store advisors. At checkout, an advisor will bring out a fresh pair and facilitate a seamless, contactless purchase.

Behind the Magic Wall, changing rooms are available to test On’s apparel collection. Stepping into the changing rooms, shoppers will feel transported to the Swiss Alps with a signature Alpine scent and complementing sounds. Upon exiting On NYC, shoppers will pass a life-size, 3D-printed boulder, another nod to On’s outdoor roots. Scanned directly from the Engadin Valley in the Swiss Alps, the piece celebrates On’s history and founding. To find out more about any touch point or product in the store, including how the boulder was made, shoppers can simply hold their smartphones to the object for instant access to more information using NFC technology.

On NYC reflects the brand’s persistent innovation and devotion to creating unique products and experiences for customers everywhere. Located in New York City’s lively NoHo neighborhood, On NYC will serve as a seasonal hub for the local running community where runners of all kinds can safely gather to run together and see the latest products from the brand. For more information about On NYC, the store’s COVID-19 safety measures and how to book a virtual appointment visit www.on-running.com/on-nyc.

Hi-res images available for download here.

About On

On was born in the Swiss Alps with one goal: to revolutionize the sensation of running. Ten years after market launch, On delivers industry-disrupting innovation in premium footwear, apparel, and accessories for high-performance running, outdoor, and all day activities. Driven by peer-recommendation, On’s award-winning CloudTec^® technology and groundbreaking strides in sportswear’s circular economy has attracted the fastest-growing global fanbase in specialty running — harnessing the human spirit through fearless performance, mindful innovation and purposeful design to empower all people to run on clouds. www.on-running.com.

Olivia Ragan, Communications Manager
847-207-6276
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/19719afa-ce44-4a41-9a85-d1c2bb24b566